CXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases
Biomolecules · 2026
DOI: 10.3390/biom16091325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Gabriele Farina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy. Hauptthemen laut MEDLINE: Chemokine CXCL10, PPAR-beta, Monocytes, PPAR delta. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The chemokine CXCL10 contributes to early autoimmune rheumatic disease (ARD) development. Preclinical ARD stages exhibit dendritic cells (DCs), CD4+ T cells, and monocytes (CD14+ cells) dysregulation and an overreactive immunoprofile. The peroxisome proliferator-activated receptor (PPAR)β/δ acts as a “molecular brake”, limiting autoimmune overresponse. This study aims to investigate CXCL10 in human monocyte-derived mDCs, CD4+ T cells, and monocytes exposed to PPARβ/δ agonist carbaprostacylin (cPGI2) or PPARγ agonist rosiglitazone (RGZ), to verify drug-class-related effects. Tumor necrosis factor (TNF)α, interferon (IFN)γ, synergistic inducers of CXCL10, and interleukin (IL)-10 were investigated. mDCs, CD4+ T cells, and CD14+ monocytes isolated from healthy donors’ blood were cultured, specifically activated to mimic an overreactive phenotype, and treated for 24–48 h with/without [10 μM] cPGI2 or [5 μM] RGZ (near therapy doses, respectively). Luminex assays quantified cell supernatant analytes; Real-time q-PCR measured cytokine and PPARβ/δ mRNA expression. cPGI2, not RGZ, significantly decreased CXCL10 in mDCs and CD4+ T cells, reduced TNFα in mDCs, CD4+ T and monocytes, and diminished IFNγ in mDCs. IL-10 did not change. cPGI2-induced CXCL10 downregulation, with TNFα and IFNγ decrease, might be relevant, given its early activity in ARD development. Scenarios on PPARβ/δ agonist re-positioning aimed at modulating CXCL10 might open opportunities to support ARD management and targeted therapy development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy.
- Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50121 Florence, Italy.
- Department of Internal Medicine and Medical Specialties, AOU Policlinico Umberto I, 00185 Rome, Italy.
- Rheumatology Unit, Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.
ORCID-Profile: Giada La Spina, Francesca Romana Spinelli, Clara Crescioli
Zitieren
APA
Farina, G., Sottili, M., La Spina, G., Gelmini, S., Truglia, S., Conti, F., Spinelli, F. R., & Crescioli, C. (2026). CXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases. Biomolecules. https://doi.org/10.3390/biom16091325
Vancouver
Farina G, Sottili M, La Spina G, Gelmini S, Truglia S, Conti F, et al. CXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases. Biomolecules. 2026. doi:10.3390/biom16091325
BibTeX
@article{Farina2026,
author = {Farina, Gabriele and Sottili, Mariangela and La Spina, Giada and Gelmini, Stefania and Truglia, Simona and Conti, Fabrizio and Spinelli, Francesca Romana and Crescioli, Clara},
title = {CXCL10 Is Inhibited by PPARβ/δ-Selective Activation in Human Monocyte-Derived Dendritic Cells, T Lymphocytes and Monocytes In Vitro: Insights into Autoimmune Rheumatic Diseases},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16091325}
}
EUVIMED